News

The Phase I/IIa trial is designed to assess the safety, tolerability and biological activity of the vaccine. CureVac expects to start the treatment of the first patient in

In his last position, he was a principal at a consulting firm he founded in 2002, providing high-level interim financial management and M&A services. Before that, Schmidt served

The primary endpoints of the oral dose escalating trial are determination of safety, tolerance and pharmacokinetic properties of CX-4945 and to select the appropriate dose for Phase II

The company has also experienced a reorder rate of over 90%. “The promise of personalized medicine is quickly becoming a reality for patients with lung and colon cancer

SurgiSeal is said to be the first and only 2-octyl cyanoacrylate that does not require an activator. It is indicated for use in surgical and emergency applications. Cyanoacrylate

Velcura earlier completed a successful Phase Ia clinical trial of VEL-0230 in healthy individuals. Importantly, a rapid and significant reduction in bone resorption was observed in individuals treated

Mr Vazquez, who earned his bachelor of arts degree in biology and JD from the University of Puerto Rico, has assembled an experienced team of sales representatives and

CardioFit is intended as a treatment for New York Heart Association class II-III heart failure patients who have failed to achieve symptomatic improvement through standard evidence based management.

Participating in the financing were existing investors Claremont Creek Ventures and Sequoia Capital as well as new investor Alafi Capital. Matthew Rabinowitz, president and CEO of Gene Security